Skip to content

Posterior arthroscopic treatment of posterior located osteochondral defects of the talus: A long-term follow up study.

Posterior arthroscopic treatment of posterior located osteochondral defects of the talus: A long-term follow up study. - Posterior arthroscopic treatment of OD's of the talus.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42318
Enrollment
40
Registered
2015-11-27
Start date
2016-05-23
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cartilage defects osteochondral defects

Interventions

None listed

Sponsors

Orthopedie
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Patients that were treated for an osteochondral defect of the talus by means of 2-portal hindfoot approach in the AMC from 1988 until 2012 - Capable of filling out a questionnaire - Signed informed consent

Exclusion criteria

Exclusion criteria: - Systemic disease (e.g. rheumatoid arthritis, lupus erythematosus) - Ankle trauma 6 months or less prior to follow-up - Painful or invalid disorder of the lower extremity - Inability to understand the patient information and the questionnaires (e.g. mental retardation, language barrier) - No informed consent

Design outcomes

Primary

MeasureTime frame
The goal of this study is to evaluate the treatment. The primary outcome measure is the subjective outcome of the patients, measured by the Berndt & Harty Outcome score, and the Ogilvie-Harris score.

Secondary

MeasureTime frame
Secondary outcome measures are the VAS pain score at rest, during walking, and during running, the AOFAS score, the SF-36, the Berndt & Harty classification of osteochondral defects of the talus and the osteoarthritis classification previously published by Van Dijk et al.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)